Advertisement
Canada markets open in 4 hours 18 minutes
  • S&P/TSX

    21,871.96
    +64.59 (+0.30%)
     
  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     
  • DOW

    38,239.98
    +253.58 (+0.67%)
     
  • CAD/USD

    0.7294
    -0.0007 (-0.09%)
     
  • CRUDE OIL

    82.31
    +0.41 (+0.50%)
     
  • Bitcoin CAD

    90,817.54
    +281.12 (+0.31%)
     
  • CMC Crypto 200

    1,394.29
    -20.47 (-1.45%)
     
  • GOLD FUTURES

    2,316.10
    -30.30 (-1.29%)
     
  • RUSSELL 2000

    1,967.47
    +19.82 (+1.02%)
     
  • 10-Yr Bond

    4.6230
    +0.0080 (+0.17%)
     
  • NASDAQ futures

    17,392.75
    +42.75 (+0.25%)
     
  • VOLATILITY

    16.67
    -0.27 (-1.59%)
     
  • FTSE

    8,049.61
    +25.74 (+0.32%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • CAD/EUR

    0.6837
    -0.0013 (-0.19%)
     

Mettrum Health Corp. Closes $15 Million Bought Deal Offering of Common Shares

TORONTO, ONTARIO--(Marketwired - Aug. 26, 2016) -

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Mettrum Health Corp. ("Mettrum" or the "Company"), (TSX VENTURE:MT), a vertically integrated provider of cannabis products, is pleased to announce that it has completed its previously announced bought deal offering of 5,661,000 common shares of the Company (the "Shares"), at a price of $2.65 per Share for aggregate gross proceeds of $15,001,650 (the "Offering").

The Offering was led by Cormark Securities Inc. and a syndicate of underwriters including Mackie Research Capital Corporation, GMP Securities L.P., Clarus Securities Inc., Dundee Securities Ltd., Echelon Wealth Partners Inc. and PI Financial Corp. (collectively, the "Underwriters").

ADVERTISEMENT

The Company has granted the Underwriters an over-allotment option to purchase up to 849,150 additional Shares. The over-allotment option may be exercised until 30 days following the closing of the Offering.

This news release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.

About Mettrum Health Corp.

Mettrum Health Corp. is a Tier 1 Industry Issuer listed on TSX Venture Exchange (the "TSXV"). Mettrum Ltd., a wholly owned subsidiary of the Company, is a Toronto-based company and a licensed producer of medical cannabis under the Access to Cannabis for Medical Purposes Regulation (the "ACMPR"), which came into effect on August 24, 2016 and replaced the Marihuana for Medical Purposes Regulations ("MMPR") . Mettrum received its first license from Health Canada under the MMPR on November 1, 2013 and began production of medical cannabis at its first production facility in Bowmanville, Ontario. Mettrum received its second license from Health Canada under the MMPR on December 11, 2014 for its other wholly-owned subsidiary, Agripharm Corp., at Mettrum Creemore facility in Clearview, Ontario. Mettrum received its third license from Health Canada under the MMPR on December 17, 2015 for Mettrum Ltd. at its new 60,000 square foot production and distribution facility in Bowmanville, Ontario. With the Company's three licenses, Mettrum is a leading producer and vendor of medical cannabis under the ACMPR system. In addition, through its wholly-owned subsidiary Mettrum Hempworks, Mettrum also is a licensed producer and distribution of industrial cannabis (hemp) products, including Mettrum's functional food line, Mettrum Originals, under the Industrial Hemp Regulations (Canada) issued pursuant to the Controlled Drugs and Substances Act (Canada).

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.